Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 51

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 51
---
 in the operation and expansion of our business. If we do not pay dividends, our stock may be less valuable to you because a return on your investment will only occur if our stock price appreciates.

Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.

Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur as a result of our utilization of a universal shelf registration statement, our Controlled Equity Offering SMSales Agreement with Cantor or otherwise could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common stock or the market perception that we are permitted to sell a significant number of our securities would have on the market price of our common stock.

The market price for our securities may be volatile, which could result in substantial losses to investors.

The market price for our common stock may be volatile and subject to wide fluctuations in response to factors including the following:

| ● | actual                                                                                
 or anticipated fluctuations in our quarterly operating results;                       |
| ● | our                                                                                   
 failure to meet or exceed securities analysts’ expectations of our financial results; |
| ● | a                                                                                     
 change in financial estimates or securities analysts’ recommendations;                |
| ● | changes                                                                               
 in management’s or securities analysts’ estimates of our financial performance;       |
| ● | future                                                                                
 sales of our common stock;                                                            |
| ● | low                                                                                   
 trading volume of our common stock;                                                   |
| ● | additions                                                                             
 or departures of key personnel; or                                                    |
| ● | results                                                                               
 of studies or patent prosecution activities.                                          |

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. As a result, to the extent shareholders sell our securities in negative market fluctuation, they may not receive a price per share that is based solely upon our business performance. We cannot guarantee that shareholders will not lose some of their entire investment in our securities.

| S-7 |

<div align='center'>USE OF PROCEEDS</div>

We intend to use the net proceeds of this offering, if any, for general corporate purposes, including, but not limited to, ongoing clinical and pre-clinical work, the development of new cancer and other healthcare related technologies, investing in